News Doubts over BACE drugs after Merck ends Alzheimer's trial Decision comes a year after Merck axed EPOCH verubecestat trial
News Axovant CEO David Hung quits after Alzheimer's drug failure Last month the biotech Axovant was rocked by the failure of its star drug intepirdine in Alzheimer’s disease – and the fall-out is still being felt, with CEO David Hung deciding to walk out.
News Boehringer latest to axe Alzheimer's drug Company will trial BI 409306 in schizophrenia instead.
News Bad week for dementia R&D after Axovant howler and another f... Axovant misreports trial results, Lundbeck Alzheimer's drug fails
News Pfizer axes Alzheimer's and Parkinson's research Big pharma will continue developing tanezumab painkiller with Lilly
Partner Content Partner Content 2018 Agenda Released: World CNS Summit Targeting Neurodegenerative Diseases
News Neurogene drops high-dose arm in Rett study after death The patient affected by a serious adverse event in Neurogene's clinical trial of Rett syndrome gene therapy has now died
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
